An improved method of delivering a sclerosing agent for the treatment of a malignant pleural effusion
Ended Project Grant Awarded Last action
- Award ID
- R44CA210696
- Recipient
-
TDL Innovations LLC UEI MU8UKBNPF3J5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,891,429
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- New Jersey, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $403 | |
| Amendment | $403 | |
| Amendment | $403 | |
| Amendment | $959,737 | |
| Original award | $930,483 |
Quick answers
Who received award R44CA210696?
R44CA210696 was awarded to TDL Innovations LLC by National Cancer Institute (National Institutes of Health) on September 1, 2017.
How much is award R44CA210696 worth?
$1,891,429 has been obligated on R44CA210696.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award